First Cancer Patients in Taiwan Treated with Varian HyperArc High-Definition Radiotherapy

PALO ALTO, Calif., Jan. 17, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced 10 patients at the Chi Mei Medical Center with brain lesions became the first patients in Taiwan to be treated using the company's HyperArc^tm High Definition Radiotherapy (HDRT), a new type of radiosurgery treatment solution.

"Having delivered SRS and SBRT treatments the past 10 years, I am very satisfied with the HyperArc treatment plan quality, especially the dose conformality and sparing of organs at risk," said Dr. Yu-Wei Lin, the senior attending physician at Chi Mei Hospital. "It's such an efficient and simple way to deliver a complicated radiation treatment plan."

"We are excited that HyperArc treatments have begun in Taiwan," said Christina Lin, managing director Taiwan for Varian's Oncology Systems business. "By working closely with leading institutions like Chi Mei Hospital to deliver advanced cancer treatments to more patients, we are taking another important step in achieving our vision of a world without fear of cancer."

The HyperArc solution is designed to automate and simplify sophisticated treatments such as stereotactic radiosurgery (SRS), and capitalizes on the unique capabilities of Varian's TrueBeam^® and EDGE^tm treatment systems. HyperArc treatments allow clinicians the ability to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue. These advanced treatments can be delivered in a conventional treatment time slot. The treatment planning for the HyperArc solution is supported by Varian's Eclipse^tm treatment planning software and ARIA^® oncology information system.

For more information on the HyperArc solution, visit www.varian.com/hyperarc

About Varian
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact

Mark Plungy
Director, Public Relations
+1 (650) 424-5630
[email protected]

Investor Relations Contact

J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

SOURCE Varian